Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
31 Mar 2020
When treating fibromyalgia patients with low-dose naltrexone, the 4.5-mg dose appears to be a good choice, according to a recent study.
Pearl Toh, 11 Jun 2019
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.

Prazosin cuts rate of drinking in patients with alcohol use disorder

10 Sep 2018
How to identify doctors hooked on drugs and alcohol

The α-1 adrenergic receptor antagonist prazosin appears to be an effective treatment for alcohol use disorder, according to a recent study.

“Prazosin holds promise as a harm-reduction pharmacologic treatment for alcohol use disorder and deserves further evaluation by independent research groups,” the authors said.

A total of 92 participants with alcohol use disorder but without post-traumatic stress disorder were randomized to receive prazosin or placebo in a 12-week double-blind study. Medication was titrated to a target dosing of 4 mg in morning and in the afternoon and 8 mg at bedtime by the end of week 2.

Medical management was the behavioural platform. Data on alcohol consumption were provided by participants daily. The authors assessed the impact of prazosin vs placebo on number of drinks per week, number of drinking days per week and number of heavy drinking days per week using generalized linear mixed-effects models.

Of the participants, 80 completed the titration and were included in the primary analyses. A significant association was seen between condition and week for both number of drinks and number of heavy drinking days. Participants in the prazosin condition had a greater reduction in the rate of drinking and the probability of heavy drinking compared with those in the placebo condition over time.

In addition, there was a higher incidence of drowsiness and oedema among participants in the prazosin vs the placebo condition.

“Current medications for alcohol use disorder do not target brain noradrenergic pathways. Theoretical and preclinical evidence suggests that noradrenergic circuits may be involved in alcohol reinforcement and relapse,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
31 Mar 2020
When treating fibromyalgia patients with low-dose naltrexone, the 4.5-mg dose appears to be a good choice, according to a recent study.
Pearl Toh, 11 Jun 2019
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.